53086-52-5

Basic information

• Product Name: 2-(3-Bromophenyl)propanoic acid
• Synonyms: 2-M-BROMOPHENYLPROPIONIC ACID;2-(3-bromophenyl)propanoicacid;2-(3-BroMophenyl)Propionic Acid
• CAS NO: 53086-52-5
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07
• Mol File: 53086-52-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 319.6 °C at 760 mmHg
• Flash Point: 147.1 °C
• Appearance: /
• Density: 1.523 g/cm³
• Vapor Pressure: 0.000139mmHg at 25°C
• Refractive Index: 1.575
• Solubility: DCM, DMSO, Diethyl Ether, Methanol
• PKA: 4.17±0.10(Predicted)
• CAS DataBase Reference: 2-(3-Bromophenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Bromophenyl)propanoic acid(53086-52-5)
• EPA Substance Registry System: 2-(3-Bromophenyl)propanoic acid(53086-52-5)

Safety Data

• Hazardous Substances Data: 53086-52-5(Hazardous Substances Data)

Usage

Uses

2-(3-Bromophenyl)propanoic Acid is an intermediate in the synthesis of Ketoprofen (K200800) related compounds.

InChI:InChI=1/C9H9BrO2/c1-6(9(11)12)7-3-2-4-8(10)5-7/h2-6H,1H3,(H,11,12)

Upstream product

• 74-88-4 methyl iodide 
• 1878-67-7 3-Bromophenylacetic acid 
• 124-38-9 carbon dioxide 
• 2725-82-8 1-bromo-3-ethylbenzene 

Downstream Products

• 1016644-45-3 3-(1-carboxy-ethyl)-phenyl boronic acid 
• 56911-40-1 fenoprofen 
• 1071454-63-1 2-{3-[3-(2-methoxy-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]-phenyl}-propionic acid 
• 81606-47-5 2-(3-bromophenyl)-2-methylpropanoic acid 
• 1161355-90-3 2-(3-methylphenyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 
• 1161355-49-2 N-(4-(2-methyl-4-pyridinyl)phenyl)-2-phenylpropanamide 
• 1161356-61-1 2-(3-(4-methyl-1-piperazinyl)phenyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 
• 1161356-62-2 N-(4-(2-methyl-4-pyridinyl)phenyl)-2-(3-(4-(2-pyridinyl)-1-piperazinyl)phenyl)-propanamide 
• 1161356-83-7 2-(4'-acetyl-3-biphenylyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 
• 1161356-82-6 n,n-dimethyl-3'-(1-methyl-2-((4-(2-methyl-4-pyridinyl)phenyl)amino)-2-oxoethyl)-4-biphenylcarboxamide 
• 1161357-66-9 2-(4'-cyano-3-biphenylyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 
• 1161356-79-1 2-(3'-cyano-3-biphenylyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 
• 1161357-67-0 2-(2'-cyano-3-biphenylyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 
• 1161357-68-1 2-(4'-methoxy-3-biphenylyl)-N-(4-(2-methyl-4-pyridinyl)phenyl)propanamide 

Relevant articles and documents

NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention provides a novel thiazole derivative or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The thiazole derivative or a pharmaceutically acceptable salt thereof according to the present invention has selective inhibitory activity against cyclin-dependent kinase (CDK) and thus can be usefully used as a preventive or therapeutic agent for various diseases associated with the CDK.

SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS

The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.